Patents Examined by Suzanne M. Noakes
  • Patent number: 11530396
    Abstract: A mutant SaCas9 protein such as a protein having an amino acid sequence resulting from mutations of glutamic acid at the 782-position to lysine (E782K), leucine at the 800-position to arginine (L800R), asparagine at the 968-position to arginine (N968R), asparagine at the 985-position to alanine (N985A), arginine at the 991-position to alanine (R991A), alanine at the 1021-position to serine (A1021S), threonine at the 927-position to lysine (T927K), lysine at the 929-position to asparagine (K929N), and isoleucine at the 1017-position to phenylalanine (I1017F) in SEQ ID NO: 2 has relaxed restriction on target sequence while maintaining binding ability to guide RNA, and is useful as a tool for gene editing.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: December 20, 2022
    Assignees: THE UNIVERSITY OF TOKYO, MODALIS THERAPEUTICS CORPORATION
    Inventors: Osamu Nureki, Hiroshi Nishimasu, Hisato Hirano, Shohei Kajimoto, Tetsuya Yamagata, Yuanbo Qin, Keith M. Connolly, Iain Thompson
  • Patent number: 11530425
    Abstract: The disclosure provides systems, methods, and compositions for a target specific nuclease and a blunting enzyme to correct frameshift mutations for genome editing and treatment of diseases. In some embodiments, the target specific nuclease and the blunting enzyme are combined with a guide RNA and/or a microhomology-mediated end joining (MMEJ) inhibitor.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: December 20, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Timothy Lu, Shota Nakade
  • Patent number: 11532377
    Abstract: Systems and methods for modeling a three-dimensional protein structure are disclosed. The method includes receiving a primary amino acid sequence of a three-dimensional protein, translating the primary amino acid sequence to a first vector, determining a per-residue conformation index for each amino acid residue in the primary amino acid sequence, determining a vector set for each amino acid residue in the primary amino acid sequence, and using the per-residue interaction vector set to generate a multi-dimensional matrix for the three-dimensional protein structure. The first vector includes a unique numerical descriptor value corresponding to each amino acid residue in the primary amino acid sequence. The vector set includes a plurality per-residue interaction factors corresponding to a plurality of conformation indexes for that amino acid residue.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: December 20, 2022
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Lawrence Williams, Brian Schendt
  • Patent number: 11525125
    Abstract: The invention relates to a new method of characterising a target polynucleotide. The method uses a pore and a Dda helicase. The helicase controls the movement of the target polynucleotide through the pore. The invention also relates to modified Dda helicases which can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: December 13, 2022
    Assignee: Oxford Nanopore Technologies PLC
    Inventors: Mark John Bruce, Andrew John Heron, Ruth Moysey, Szabolcs Soeroes, Elizabeth Jayne Wallace, James White
  • Patent number: 11525126
    Abstract: The invention relates to modified helicases with reduced unbinding from polynucleotides. The helicases can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.
    Type: Grant
    Filed: October 6, 2020
    Date of Patent: December 13, 2022
    Assignee: Oxford Nanopore Technologies PLC
    Inventors: Andrew Heron, Anthony Clarke, Ruth Moysey, Elizabeth Jayne Wallace, Mark John Bruce, Lakmal Jayasinghe, Domenico Caprotti, Szabolcs Soeroes, Luke McNeill, David Antoni Alves, Rebecca Victoria Bowen, John Milton
  • Patent number: 11519025
    Abstract: The invention is in the field of regulation of enzymatic activity in nucleic acid modifying reactions. It describes a method of regulating enzymatic activity by adding chelating agents to the reaction composition and exploits the fact that both the binding of divalent cations to these chelating agents and the pH of commonly used buffers is temperature dependent. PCR experiments that are hampered by non-specific side products can be regulated such that the target sequence is amplified in a more specific manner.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: December 6, 2022
    Assignee: QIAGEN GmbH
    Inventors: Alexander Azzawi, Ralf Peist
  • Patent number: 11505797
    Abstract: The disclosure provides a guide RNA (gRNA) comprising a DNA-binding domain and a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease protein-binding domain, wherein the DNA-binding domain is complementary to a target domain from a variant NRF2 gene found in a cancer cell but not in a non-cancerous cell. The disclosure also provides nucleic acid sequence encoding the gRNA. The disclosure further provides a method of treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease and a guide RNA that is complementary to a target domain from a variant NRF2 gene in the subject.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: November 22, 2022
    Assignee: Christiana Care Health Services, Inc.
    Inventors: Eric Kmiec, Pawel Bialk
  • Patent number: 11499169
    Abstract: The present invention is directed to methods and compositions for typing of Lactobacillus buchneri bacterial strains, detecting the presence of a L. buchneri in a sample, identifying a strain of L. buchneri having resistance to an invasive foreign genetic element, modifying the resistance of bacteria and archeae to an invasive foreign genetic element, and introducing nicks into or cleaving double stranded DNA for genome editing.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: November 15, 2022
    Assignee: North Carolina State University
    Inventors: Rodolphe Barrangou, Alexandra Briner Crawley
  • Patent number: 11492651
    Abstract: Methods and compositions for making bacteriocins are described in some embodiments herein. In some embodiments, pro-polypeptide comprising the bacteriocins in the desired ratios in cis, and separated by cleavage sited can be produced by a microbial cell comprising a nucleic acid encoding the pro-polypeptide. In some embodiments microfluidic devices and methods for making specified mixtures of antimicrobial peptides and/or bacteriocins are described.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: November 8, 2022
    Assignee: Syngulon SA
    Inventor: Philippe Gabant
  • Patent number: 11479776
    Abstract: A protein expression system for use in a prokaryotic host is provided, the expression system comprising: a) an expression cassette comprising a nucleic acid sequence encoding a protein of interest operably linked to a T7 RNA polymerase-dependent promoter; and b) an expression cassette comprising a nucleic acid sequence encoding T7 RNA polymerase operably linked to a host polymerase-dependent ? phage promoter and a single perfect palindrome operator sequence; wherein the expression cassette for T7 RNA polymerase is located on the chromosome of a host cell.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: October 25, 2022
    Assignee: Fujifilm Diosynth Biotechnologies UK Limited
    Inventor: Christopher Lennon
  • Patent number: 11479762
    Abstract: This disclosure provides compositions, recombinant expression constructs, and engineered systems that include a polynucleotide including or encoding a Cas12a tracrRNA, and methods for their use. The materials and methods of the disclosure are especially suited to sequence-specific genome editing of eukaryotic genomic sequences.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: October 25, 2022
    Assignee: INARI AGRICULTURE TECHNOLOGY, INC.
    Inventors: Adam Patrick Joyce, Michael Andreas Kock
  • Patent number: 11479780
    Abstract: Epigenomic states of genome DNA are altered at multiple sites to rapidly change traits by providing a fusion protein including a first region that defines a polypeptide capable of binding sequence-specifically to multiple sites on genome DNA and a second region that defines a polypeptide capable of regulating an epigenomic state.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: October 25, 2022
    Assignee: KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO
    Inventors: Hidenori Tanaka, Akinori Ikeuchi, Risa Onoda, Hiroki Sugimoto, Nobuhiko Muramoto
  • Patent number: 11473070
    Abstract: The presently-disclosed subject matter describes fusion proteins comprising butyrylcholinesterase (BChE) having an improved production yield and biological half-life and nucleotides encoding the same.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: October 18, 2022
    Assignee: University of Kentucky Research Foundation
    Inventors: Chang-Guo Zhan, Fang Zheng
  • Patent number: 11473073
    Abstract: The present disclosure provides polypeptides having aminopeptidase activity and isolated nucleic acid sequences encoding the polypeptides. In some embodiments, the disclosure also provides to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the polypeptides. In some embodiments, the present disclosure further provides to methods of obtaining protein hydrolysates useful as flavor improving agents.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: October 18, 2022
    Assignee: Dupont Nutrition Biosciences APS
    Inventors: Karsten Matthias Kragh, Ernst Meinjohanns, Thomas Eisele, Peter Edvard Degn, Steffen Yde Bak
  • Patent number: 11473066
    Abstract: The present invention provides chimeric Flp-TAL recombinases, as well as nucleic acids, and methods for the use of the chimeric Flp-TAL recombinases for site-specific alteration of a target sequence in cells.
    Type: Grant
    Filed: November 9, 2019
    Date of Patent: October 18, 2022
    Inventor: Yuri Voziyanov
  • Patent number: 11472854
    Abstract: New insecticidal proteins, nucleotides, peptides, their expression in plants, methods of producing the peptides, new processes, production techniques, new peptides, new formulations, and new organisms, a process which increases the insecticidal peptide production yield from yeast expression systems. The present invention is also related and discloses selected endotoxins we call cysteine rich insecticidal peptides (CRIPS) which are peptides derived from Bacillus thuringiensis (Bt) and their genes and endotoxins in combination with toxic peptides known as Inhibitor Cystine Knot (ICK) genes and peptides as well as with other types of insecticidal peptides such as trypsin modulating oostatic factor (TMOF) peptide sequences used in various formulations and combinations; of both genes and peptides, useful for the control of insects.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: October 18, 2022
    Assignee: Vestaron Corporation
    Inventors: Robert M. Kennedy, William Tedford, Christopher Hendrickson, Robert Venable, Catherine L. Foune, John McIntyre, Alvar R. Carlson, Lin Bao
  • Patent number: 11473092
    Abstract: One objective of the present invention is to provide a novel simple and efficient transformation method for gram-positive bacteria, the transformation method being capable of introducing a large-sized DNA into a host DNA of the gram-positive bacteria without damage. In addition, another objective of the present invention is to provide a method in which desired DNA segments are accumulated in a chromosome of a recipient (recipient bacteria) to enable an artificially designed huge DNA to be constructed, and in which a transformed cell does not cause any problems in terms of controlling the natural environment. The present invention relates to a transformation method for gram-positive bacteria by conjugative transfer, characterized to use a helper plasmid having an origin of DNA transfer (oriT) region is inactivated. Preferably, the helper plasmid is a plasmid in which an oriT region is inactivated from pLS20cat.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: October 18, 2022
    Assignee: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY
    Inventor: Kenichi Yoshida
  • Patent number: 11473110
    Abstract: Provided herein are Metschnikowia species that produce xylitol from xylose when cultured, as well as methods to make and use these Metschnikowia species.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: October 18, 2022
    Assignee: Creatus Biosciences Inc.
    Inventors: Zongli Luo, Hendrik Jurgens Jansen Van Vuuren, Allan George DeBono, Andrew Taplin Ferguson
  • Patent number: 11472851
    Abstract: The present invention provides a recombinant Bacillus subtilis JY011802 that can produce sublancin in a high yield, which was deposited at the China General Microbiological Culture Collection Center on Oct. 31, 2018 with an accession number of CGMCC No. 16667, and an application thereof. The yield of the sublancin produced by the recombinant Bacillus subtilis can reach 3100 mg/L.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: October 18, 2022
    Assignee: HUZHOU JlUYUAN BIO-TECH CO, LTD.
    Inventor: Liangxing Guo
  • Patent number: 11473068
    Abstract: The present invention provides several non-naturally occurring sulfotransferase enzymes that have been engineered to react with aryl sulfate compounds as sulfo group donors, instead of the natural substrate 3?-phosphoadenosine 5?-phosphosulfate (PAPS), and with heparosan-based polysaccharides, particularly heparan sulfate, as sulfo group acceptors. Each of the engineered sulfotransferase enzymes have a biological activity characterized by the position within the heparosan-based polysaccharide that receives the sulfo group, including glucosaminyl N-sulfotransferase activity, hexuronyl 2-O sulfotransferase activity, glucosaminyl 6-O sulfotransferase activity, or glucosaminyl 3-O sulfotransferase activity. Methods of using the engineered sulfotransferases to produce sulfated heparosan-based polysaccharides, including polysaccharides having anticoagulant activity, are also provided.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: October 18, 2022
    Assignee: OPTIMVIA, LLC
    Inventor: Tarsis Gesteira Ferreira